This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Find the latest science, technology and partners in antibody engineering, immunobiology and next generation binders.

Antibody Engineering and Therapeutics Survey: Tell us your views

Share this article

There are a number of different antibody therapeutic modalities the industry is working on - from mAbs, to bispecifics, to ADCs - increasingly exploring new non-cancer targets. Each therapeutic type and target brings its own set of challenges, opportunities and strategies, as well as corresponding technologies and platforms.

The Antibody Engineering & Therapeutics conference series is conducting a survey of industry professionals from around the world. The final report will reveal unique insights into the hottest potential opportunities and the biggest challenges around antibody therapeutic modalities and targets.

Click here to take part in the survey.

Completing the survey will take just 5 minutes and will give you exclusive early access to the final report. All answers will remain anonymous. Plus, everyone who completes the survey by Sunday 17th May 2020 will be entered into a prize draw for a free conference pass to their choice of Informa Connect Antibody Engineering & Therapeutics conference (full terms and conditions can be found here):

We’re excited to see the results of this study and we hope you are too.

Click here to take part in the survey.

Share this article

Upcoming event

Antibody Engineering & Therapeutics US

04 - 08 Dec 2022, Delivered as a Hybrid Event
Go to site